


Karsten Schrör

 WILEY-
BLACKWELL

Acetylsalicylic Acid



Contents

Preface *XI*

1 General Aspects 3

- 1.1 History 5
 - 1.1.1 Willow Bark and Leaves as Antipyretic, Anti-Inflammatory Analgesics 5
 - 1.1.2 Salicylates as the Active Ingredient of Willow Bark and Other Natural Sources 6
 - 1.1.3 Synthesis of Acetylsalicylic Acid and First Clinical Studies 7
 - 1.1.4 Mode of Aspirin Action 12
 - 1.1.5 Anti-Inflammatory/Analgesic Actions of Aspirin 14
 - 1.1.6 Aspirin in the Cardiovascular System 15
 - 1.1.7 Current Research Topics 17
- 1.2 Chemistry 25
 - 1.2.1 Structures and Chemical Properties of Salicylates 25
 - 1.2.1.1 Salicylates in Clinical Use 25
 - 1.2.1.2 Aspirin Formulations 27
 - 1.2.2 Determination of Salicylates 30
 - 1.2.2.1 Gas-Liquid Chromatography 30
 - 1.2.2.2 High-Performance Liquid Chromatography 30
 - 1.2.2.3 Spectrophotometry 30

2 Pharmacology 33

- 2.1 Pharmacokinetics 35
 - 2.1.1 Absorption and Distribution 36
 - 2.1.1.1 Absorption 36
 - 2.1.1.2 Particular Aspirin Formulations 40
 - 2.1.1.3 Distribution 40
 - 2.1.1.4 Modifying Factors 42
 - 2.1.2 Biotransformation and Excretion 46
 - 2.1.2.1 Biotransformation of Aspirin 46
 - 2.1.2.2 Biotransformations of Salicylic Acid 48
 - 2.1.2.3 Excretion of Salicylates 49

2.1.2.4	Modification of Biotransformations and Excretion of Salicylates	50
2.2	Cellular Modes of Action	53
2.2.1	Inhibition of Cyclooxygenases	54
2.2.1.1	Acetylation of Cyclooxygenases and Traditional NSAIDs	55
2.2.1.2	Modulation of COX-2 Gene Expression	61
2.2.1.3	Further Actions of Salicylates on Arachidonate Metabolism	62
2.2.2	COX-Independent Actions on Cell Function	66
2.2.2.1	Kinases	67
2.2.2.2	Transcription Factors	69
2.2.2.3	Oxidative Stress and Nitric Oxide	73
2.2.2.4	Immune Responses	75
2.2.3	Energy Metabolism	79
2.2.3.1	Fatty Acid β -Oxidation	80
2.2.3.2	Uncoupling of Oxidative Phosphorylation	82
2.2.3.3	Toxic Actions of Salicylates on the Liver	84
2.3	<i>Actions on Organs and Tissues</i>	88
2.3.1	Hemostasis and Thrombosis	89
2.3.1.1	Platelets	90
2.3.1.2	Endothelial Cells	95
2.3.1.3	Plasmatic Coagulation	98
2.3.1.4	Fibrinolysis	98
2.3.2	Inflammation, Pain, and Fever	105
2.3.2.1	Inflammation	106
2.3.2.2	Pain	110
2.3.2.3	Fever	113
2.3.3	Aspirin and Malignancies	120
2.3.3.1	COX-Related Antitumor Effects of Aspirin	120
2.3.3.2	Nonprostaglandin-Related Antitumor Actions of Aspirin	122
2.3.3.3	Nonspecific Actions of Salicylates	124
3	Toxicity and Drug Safety	129
3.1	Systemic Side Effects	131
3.1.1	Acute and Chronic Toxicity	132
3.1.1.1	Occurrence and Symptoms	132
3.1.1.2	Treatment	136
3.1.1.3	Habituation	139
3.1.2	Bleeding Disorders	142
3.1.2.1	Prolongation of Bleeding Time by Aspirin	142
3.1.2.2	Aspirin-Related Bleeding Risk in Surgical Interventions	144
3.1.2.3	Aspirin, Other Drugs, and Alcohol	146
3.1.2.4	Prevention and Treatment of Bleedings	146
3.1.3	Safety Pharmacology in Particular Life Situations	150
3.1.3.1	Pregnancy and Fetal Development	150
3.1.3.2	The Elderly Patient	153
3.2	Organ Toxicity	157

3.2.1	Gastrointestinal Tract	157
3.2.1.1	Pathophysiology of GI Injury	158
3.2.1.2	Prostaglandins and Gastric Mucosal Protection	160
3.2.1.3	Mode of Aspirin Action	161
3.2.1.4	Helicobacter pylori	164
3.2.1.5	Clinical Studies	166
3.2.1.6	Aspirin and Other Drugs	170
3.2.2	Kidney	179
3.2.2.1	Analgesic Nephropathy	179
3.2.2.2	Mode of Aspirin Action	180
3.2.2.3	Clinical Studies	181
3.2.3	Liver	187
3.2.3.1	Drug-Induced Liver Injury	187
3.2.3.2	Mechanisms of Aspirin Action	187
3.2.3.3	Aspirin and Other Drugs	188
3.2.4	Audiovestibular System	191
3.2.4.1	Pathophysiology of Hearing and Equilibrium Disturbances	191
3.2.4.2	Mode of Aspirin Action	191
3.2.4.3	Aspirin, Arachidonic Acid, and Prostaglandins	193
3.2.4.4	Clinical Trials	193
3.3	Non-Dose-Related (Pseudo)allergic Actions of Aspirin	197
3.3.1	Aspirin Hypersensitivity (Widal's Syndrome)	197
3.3.1.1	Pathophysiology and Clinics	197
3.3.1.2	Mode of Aspirin Action	199
3.3.1.3	Clinical Trials	201
3.3.2	Urticaria/Angioedema, Stevens–Johnson and Lyell Syndromes	205
3.3.2.1	Urticaria/Angioedema	205
3.3.2.2	Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis (Lyell Syndrome)	206
3.3.3	Reye's Syndrome	208
3.3.3.1	Clinics, Laboratory, and Morphological Findings	209
3.3.3.2	Etiology	209
3.3.3.3	Clinical Studies	212
3.3.3.4	Actual Situation	217
4	Clinical Applications of Aspirin	223
4.1	Thromboembolic Diseases	227
4.1.1	Coronary Vascular Disease	228
4.1.1.1	Thrombotic Risk and Mode of Aspirin Action	229
4.1.1.2	Clinical Trials: Primary Prevention in Individuals Without Risk Factors	231
4.1.1.3	Clinical Trials: Primary Prevention in Individuals with Risk Factors	235
4.1.1.4	Clinical Trials: Stable Angina Pectoris	237
4.1.1.5	Clinical Trials: Secondary Prevention	238
4.1.1.6	Clinical Trials: Percutaneous Coronary Interventions	243
4.1.1.7	Clinical Trials: Coronary Artery Bypass Graft Surgery (CABG)	244
4.1.1.8	Aspirin and Other Drugs	246

4.1.1.9	Actual Situation	250
4.1.2	Cerebrovascular Diseases	260
4.1.2.1	Thrombotic Risk and Mode of Aspirin Action	261
4.1.2.2	Clinical Trials: Primary Prevention	263
4.1.2.3	Clinical Trials: Secondary Prevention	265
4.1.2.4	Aspirin and Other Drugs	267
4.1.2.5	Actual Situation	270
4.1.3	Peripheral Arterial Disease	276
4.1.3.1	Thrombotic Risk and Mode of Aspirin Action	276
4.1.3.2	Clinical Trials: Primary Prevention	278
4.1.3.3	Clinical Trials: Secondary Prevention	279
4.1.3.4	Clinical Trials: Peripheral Transluminal Angioplasty (PTA)	281
4.1.3.5	Aspirin and Other Drugs	282
4.1.3.6	Actual Situation	283
4.1.4	Venous Thrombosis	287
4.1.4.1	Thrombotic Risk and Mode of Aspirin Action	287
4.1.4.2	Clinical Trials	287
4.1.4.3	Actual Situation	288
4.1.5	Preeclampsia	290
4.1.5.1	Thrombotic Risk and Mode of Aspirin Action	290
4.1.5.2	Clinical Trials	293
4.1.5.3	Clinical Trials in Pregnancy-Induced Hypertension: Reasons for Data Variability	294
4.1.5.4	Actual Situation	298
4.1.6	Aspirin "Resistance"	303
4.1.6.1	Definition and Types of Pharmacological Aspirin "Resistance"	304
4.1.6.2	Detection of Aspirin "Resistance"	304
4.1.6.3	Pharmacological Mechanisms of Aspirin "Resistance"	307
4.1.6.4	Clinical Trials	310
4.2	Pain, Fever, and Inflammatory Diseases	322
4.2.1	Aspirin as an Antipyretic Analgesic	322
4.2.1.1	Fever, Pain, and Antipyretic/Analgesic Actions of Aspirin	323
4.2.1.2	Clinical Trials	326
4.2.1.3	Aspirin and Other Drugs	327
4.2.1.4	Actual Situation	328
4.2.2	Arthritis and Rheumatism	332
4.2.2.1	Pathophysiology and Mode of Aspirin Action	332
4.2.2.2	Clinical Trials	334
4.2.2.3	Aspirin and Other Drugs	335
4.2.2.4	Actual Situation	336
4.2.3	Kawasaki Disease	339
4.2.3.1	Pathophysiology and Mode of Aspirin Action	339
4.2.3.2	Clinical Trials	340
4.2.3.3	Aspirin and Other Drugs	341
4.2.3.4	Actual Situation	341
4.3	Further Clinical Indications	343

4.3.1	Colorectal Cancer	343
4.3.1.1	Etiology and Pathophysiology of Intestinal Adenomas, Colorectal Cancer, and Mode of Aspirin Action	344
4.3.1.2	Clinical Trials: Epidemiological Studies	346
4.3.1.3	Clinical Trials: Randomized Prospective Prevention Trials	349
4.3.1.4	Aspirin and Other Drugs	352
4.3.1.5	Actual Situation	352
4.3.2	Alzheimer's Disease	359
4.3.2.1	Pathophysiology and Mode of Aspirin Action	359
4.3.2.2	Clinical Trials	361
4.3.2.3	Aspirin and Other Drugs	363
4.3.2.4	Actual Situation	363

Appendix A 367

Appendix B 369

Index 371